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Abstract
Background: Although SLC22A12 258X allele was found among those with hypouricemia, it was unknown that
serum uric acid distribution among those with SLC22A12 258X allele. This study examined serum uric acid (SUA)
distribution according to SLC22A12 W258X genotype in a general Japanese population.
Methods: Subjects were 5,023 health checkup examinees (3,413 males and 1,610 females) aged 35 to 69 years
with creatinine < 2.0 mg/dL, who were participants of a cohort study belonging to the Japan Multi-Institutional
Collaborative Cohort Study (J-MICC Study). SLC22A12 W258X was genotyped with a polymerase chain reaction with
confronting two-pair primers.
Results: The genotype frequency was 4,793 for WW, 225 for WX, and 5 for XX, which was in Hardy-Weinberg
equilibrium (p = 0.164) with X allele 0.023 (95% confidence interval [0.021-0.027]). Mean (range) SUA was 6.2 (2.1-
11.4) mg/dL for WW, 3.9 (0.8-7.8) mg/dL for WX, and 0.8 (0.7-0.9) mg/dL for XX among males, and 4.5 (1.9-8.9) mg/
dL, 3.3 (2.0-6.5) mg/dL, and 0.60 (0.5-0.7) mg/dL among females, respectively. Six individuals with SUA less than
1.0 mg/dL included two males with XX genotype, one male with WX genotype, and three females with XX
genotype. Subjects with WX genotype were 14 (77.8%) of 18 males with a SUA of 1.0-2.9 mg/dL, and 28 (34.6%) of
81 females with the same range of SUA. The corresponding values were 131 (25.1%) of 522 males and 37 (3.5%) of
1,073 females for SUA 3.0-4.9 mg/dL, and 8 (0.4%) of 2,069 males and 5 (1.1%) of 429 females for SUA 5.0-6.9 mg/
dL. The X allele effect for SUA less than 3 mg/dL was significantly (p < 0.001) higher in males (OR = 102.5, [33.9-
309.8]) than in females (OR = 25.6 [14.4-45.3]).
Conclusions: Although SLC22A12 W258X was a determining genetic factor on SUA, SUA of those with WX
genotype distributed widely from 0.8 mg/dL to 7.8 mg/dL. It indicated that other genetic traits and/or lifestyle
affected SUA of those with WX genotype, as well as those with WW genotype.
Background
It is well known that the mean serum uric acid (SUA) is
lower in females than in males. In addition, it is fully
documented that age, menopause, food consumption,
alcohol intake, obesity, a sedentary lifestyle, dyslipide-
mia, insulin resistance, blood pressure, renal function,
and drug use for hypertension were associated with
SUA levels [1-6]. Meanwhile, recent studies have eluci-
dated that genotypes are also influential factors of SUA.
SUA is reabsorbed in renal tubules through uric acid
transporter 1 (URAT1) encoded by SLC22A12 in chro-
mosome 11q13 [7,8]. SLC22A12 was documented to
have functional polymorphisms, among which W258X
was found among those with renal hypouricemia [9-11].
However, the distribution of SUA among those with
258X allele was not reported in a general population.
This study aimed to examine SUA distribution accord-
ing to SLC22A12 W258X genotye, elucidating the over-
all effect of SLC22A12 W258X on SUA among Japanese.
Methods
This study was approved by the Ethics Committee
of Nagoya University School of Medicine (approval
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number 288). Subjects who gave written informed con-
sent to participate in the study were enrolled.
Subjects and data collection
Subjects were derived from 5,040 examinees aged 35-69
years who visited a health checkup center in
Hamamatsu, Japan in 2006-2007. They were enrolled as
participants of a cohort study belonging to the Japan
Multi-Institutional Collaborative Cohort Study (J-MICC
Study) [12,13]. As of October, 2010, one participant was
found to be ineligible in terms of age (34 years old at
enrollment), and 11 participants withdrew from the
study. Blood sample was not available for one partici-
pant, and genotyping was not successful for another.
Three participants with creatinine of 2.0 mg/dL or over
were excluded from the analysis, leaving 5,023 subjects
for the analysis.
Health checkup data including blood tests were used
for this study. Peripheral blood was drawn in the morn-
ing from those fasting overnight. Biochemical analysis of
the sampled sera was performed using an auto-analyzer
in the health checkup center.
Genotyping
DNA was extracted from buffy coat conserved at -80°C
using a BioRobot® M48 (QIAGEN Group, Tokyo).
SLC22A12 W258X polymorphism was genotyped by a
polymerase chain reaction with confronting two-pair
primers (PCR-CTPP) [14]. Each 25 μl reaction tube con-
tained 30-80 ng DNA, 0.12 mM dNTP, 12.5 pmol of
each primer, 0.5 U AmpliTaq Gold (Perkin-Elmer, Fos-
ter City, CA) and 2.5 μl of 10x PCR buffer including
15 mM MgCl2. The PCR-CTPP was conducted with
initial denaturation at 95°C for 10 minutes, 35 cycles of
denaturation at 95°C for 1 minute, annealing at 62°C for
1 minute, and extension at 72°C for 1 minute, and a
final extension at 72°C for 5 minutes. The primers were
F1: 5’- TCC ATG CAG GCT CCA GG -3’, R1: 5’- ACC
ACC AGC TGC AGC AGT GTT -3’, F2: 5’- TAC GGT
GTG CGG GAC TGG -3’, and R2: 5’- GGC AGG ATC
TCC TCT GAG G -3’. The amplified DNA fragments
were 117-base pairs (bp) for the W allele (G allele), 176-
bp for the X allele (A allele), and 255-bp for a common
band, as demonstrated in Figure 1.
Statistical analysis
Body mass index (BMI) was calculated by weight (kg)/
squared height (m2). Hardy-Weinberg equilibrium was
examined with a chi-square test. Binomial distribution
was used to estimate 95% confidence interval (CI) of
proportions. Means among the three genotype groups
were tested with analysis of variance (ANOVA).
Adjusted odds ratio (OR) and 95% CI were estimated
using an unconditional logistic model. All statistical
analyses were performed using STATA software version
11 (STATA, College Station, TX).
Results
Table 1 shows the characteristics of the 5,023 subjects
(3,413 males and 1,610 females). Those with a SUA less
than 3.0 mg/dL were 0.6% in males and 5.2% in females,
while those with a SUA of 7.0 mg/dL or over were
23.5% in males and 1.5% in females. The genotype fre-
quency was 4,793 for WW, 225 for WX, and 5 for XX,
which was in Hardy-Weinberg equilibrium (p = 0.164);
the X allele frequency was 0.023 (95% CI, 0.021-0.027).
The means of age, BMI, blood pressure, and blood
tests according to the genotype and sex are listed in
Table 2. The null hypothesis that the means were equal
among the three genotypes was rejected with one-way
ANOVA for creatinine and glucose in males, and for
age and gamma-glutamyltransferase (GGT) in females.
When the WX and XX were combined, the difference in
the mean between the combined and the WW became
nonsignificant for GGT in females, but still significant
for creatinine and glucose in males and age in females.
Mean SUA was 6.21 mg/dL forWW, 3.95 mg/dL forWX,
and 0.80 mg/dL for XX among males, and 4.50 mg/dL,
Figure 1 Representative gel for SLC22A12 W258X polymorphism.
Lane M, a 100 bp ladder; lane 1, a WW homozygote with fragments of
117 bp and 255 bp; lane 2, a WX heterozygote with fragments of 117
bp and 176 bp and 255 bp; lane 3, a XX homozygote with fragments
of 176 bp and 255 bp.
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3.31 mg/dL, and 0.60 mg/dL among females, respectively.
The difference in mean SUA between WX and WW geno-
types was significantly (p = 8E-12) higher in males
(2.26 mg/dL) than in females (1.19 mg/dL). The difference
among three genotypes was highly significant both in males
(p < 1E-40) and females (p = 1E-33). Table 3 demonstates
the SUA distribution in percentage according to the geno-
type. All five individuals with XX genotype had a SUA of
less than 1.0 mg/dL; the range was 0.7 mg/dL to 0.9 mg/dL
in males and 0.5 mg/dL to 0.7 mg/dL in females. The SUA
of those with WX genotype varied from 0.8 mg/dL to 7.8
mg/dL in males and from 2.0 mg/dL to 6.5 mg/dL in
females, while the corresponding values for those withWW
genotype were 2.1 mg/dL to 11.4 mg/dL in males and 1.9
mg/dL to 8.9 mg/dL in females. Subjects withWX genotype
were 14 (77.8%) of 18 males with SUA 1.0-2.9 mg/dL, and
28 (34.6%) of 81 females with the same range of SUA. The
corresponding values were 131 (25.1%) of 522 males and 37
(3.5%) of 1,073 females for SUA 3.0-4.9 mg/dL, and 8
(0.4%) of 2,069 males and 5 (1.1%) of 429 females for SUA
5.0-6.9 mg/dL, as depicted in Figure 2.
The age-adjusted OR (95% CI) of SUA < 3 mg/dL for
the X allele was significantly (p < 0.001) higher in males
(OR = 102.5, 95% CI, 33.9-309.8) than in females (OR =
25.6, 95% CI, 14.4-45.3). The corresponding ORs were
reduced for SUA < 4 mg/dL, as shown in Table 4.
Among those with BMI < 25 kg/m2, the age-adjusted
OR (95% CI) was 116.3 (32.5-416.8) in 2,514 males and
23.3 (12.7-42.9) in 1,355 females, while they were 78.6
(8.4-731.5) in 899 males with BMI > 25 kg/m2 and 56.2
(9.9-320.4) in 255 females with BMI > 25 kg/m2. When
these ORs were adjusted for creatinine and glucose in
males and for GGT in females, no substantial differ-
ences were observed; for example, the OR of SUA <
3 mg/dL for X allele was 89.8 instead of 102.5 in males
and 30.7 instead of 25.6 in females.
Discussion
This study demonstrated the SUA distribution according
to SLC22A12 W258X genotype in a general Japanese
Table 1 Characteristics of subjects according to sex
Characteristics Males Females
N (%) N (%)
Total 3,413 (100) 1,610 (100)
Age (years)
35-39 265 (7.8) 192 (11.9)
40-49 983 (28.8) 495 (30.7)
50-59 1,366 (40.0) 630 (39.1)
60-69 799 (23.4) 293 (18.2)
SUA (mg/dL)
-3.0 21 (0.6) 84 (5.2)
3.0-4.9 522 (15.3) 1,073 (66.6)
5.0-6.9 2,069 (60.6) 429 (26.6)
7.0- 801 (23.5) 24 (1.5)
BMI (kg/m2)*
-18.4 90 (2.6) 160 (9.9)
18.5-24.9 2,423 (71.0) 1,195 (74.2)
25.0- 899 (26.3) 255 (15.8)
Creatinine (mg/dL)
0.0-0.4 0 (0.0) 33 (2.1)
0.5-0.9 2,710 (79.4) 1,574 (97.8)
1.0-1.4 701 (20.5) 3 (0.2)
1.5-1.9 2 (0.1) 0 (0.0)
SLC22A12 W258X
WW 3,256 (95.4) 1,537 (95.5)
WX 155 (4.5) 70 (4.3)
XX 2 (0.1) 3 (0.2)
SUA, serum uric acid; BMI, body mass index.
*BMI was not available for one male.
Table 2 Characteristics of subjects according to SLC22A12 W258X genotype
Characteristics Males Females
WW WX XX P WW WX XX p
n = 3,256 n = 155 n = 2 n = 1,537 n = 70 n = 3
Age (years) 50.6 52.0 52.5 0.166 49.1 51.4 58.3 0.017
Body mass index (kg/m2) 23.5 23.7 20.9 0.240 22.0 21.9 19.7 0.407
Systolic blood pressure (mmHg) 121.0 120.5 105.0 0.319 114.4 115.1 119.3 0.811
Diastolic blood pressure (mmHg) 76.3 76.0 66.0 0.350 69.9 70.4 66.7 0.798
Total cholesterol (mg/dL) 202.3 202.7 195.5 0.944 207.2 208.9 197.3 0.793
HDL cholesterol (mg/dL) 57.7 56.0 63.5 0.338 71.1 69.7 88.3 0.159
Triglyceride (mg/dL) 124.7 129.0 66.0 0.460 85.1 85.2 73.3 0.895
AST (U/dL) 22.4 22.4 18.0 0.890 19.5 20.5 27.0 0.071
ALT (U/L) 25.5 26.6 18.5 0.732 17.1 19.5 24.7 0.066
GGT (U/L) 47.0 45.9 24.5 0.817 23.2 25.0 56.3 0.023
Creatinine (mg/dL) 0.86 0.82 0.90 0.001* 0.61 0.62 0.63 0.750
Blood urea nitrogen (mg/dL) 14.3 14.5 16.0 0.567 13.1 14.0 15.0 0.057
Blood glucose (mg/dL) 101.9 107.0 90.5 0.003* 93.7 95.2 89.7 0.434
HDL, high-density lipoprotein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyltransferase.
p-value was calculated from one-way analysis of variance among WW, WX, and XX genotypes.
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population. The SUA of all five subjects with XX geno-
type was less than 1 mg/dL, while SUA of those with
WX genotype distributed widely; from 0.8 mg/dL to
7.8 mg/dL in males and from 2.0 mg/dL to 6.5 mg/dL
in females. The difference in the mean SUA between
WX and WW genotypes was 2.26 mg/dL in males and
1.19 mg/dL in females, indicating that the reduction of
the mean SUA due to possessing X allele was signifi-
cantly larger in males than in females. Since the distri-
bution among the males with WX genotype was closer
Table 3 Serum uric acid (SUA) distribution (%) according to SLC22A12 W258X among Japanese health checkup
examinees
Genotype N SUA (mg/dL)
0.0-0.9 1.0-1.9 2.0-2.9 3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9 7.0-7.9 8.0-8.9 9.0- Mean S.D.
Males
WW 3,256 0.0 0.0 0.1 1.6 10.4 31.4 31.9 17.4 6.1 1.0 6.21 1,12
WX 155 0.6 0.0 9.0 40.0 44.5 3.2 1.9 0.6 0.0 0.0 3.95 0.83
XX 2 100.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.80 0.14
Total 3,413 0.1 0.0 0.5 3.3 12.0 30.1 30.5 16.7 5.9 0.9 6.10 1.21
Females
WW 1,537 0.0 0.1 3.4 24.9 42.5 22.8 4.7 1.2 0.3 0.0 4.50 0.94
WX 70 0.0 0.0 40.0 38.6 14.3 5.6 1.4 0.0 0.0 0.0 3.31 0.89
XX 3 100.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.60 0.10
Total 1,610 0.2 0.1 5.0 25.5 41.2 22.0 4.6 1.2 0.3 0.0 4.44 0.98
*95% CI: 95% confidence interval for SUA mean.
Figure 2 Percentages of SLC2A9 W258X genotype according to serum uric acid levels.
Hamajima et al. BMC Medical Genetics 2011, 12:33
http://www.biomedcentral.com/1471-2350/12/33
Page 4 of 6
to that among the females with WW genotype (Table 3),
the effect of X allele on SUA was similar to the effect of
sex difference. BMI did not significantly modify the
effect of the X allele on SUA both for males and
females. These findings were actually new for the asso-
ciations between SLC22A12 W258X and SUA.
Among Japanese, the frequency of 258X allele was
0.024 among 1,875 participants of a cohort study [11],
0.023 among 980 controls in a case-control study [15],
and 0.025 among 5,165 participants from another cohort
study [16], which were quite similar to the estimate in
the present study (0.023). Among Koreans, 258X allele
was found in 3 of 5 hypouricemia patients [17], and was
1.1% in a general population [18]. Since this allele has
not been reported among other ethnic groups to date,
the origin was thought to be in East Asia [19].
Several genotypes affecting SUA have been reported to
date. ABCG2 in chromosome 4q22 coding ATP-binding cas-
sette subfamily G member 2 has functional polymorphisms,
Q126X (rs72552713) and Q141K (rs2231142), with a minor
allele frequency of 0.018 and 0.281 in Japanese, respectively
[20]. Although the genotypes with reduced function increase
the risk of hyperuricemia [20-22], 126X was rare and 141K
was less influential on SUA. SLC2A9 in chromosome 4p16-
p15.3 coding glucose transporter 9 (GLUT9) was reported to
have mutations (R380W and R198C in Japanese [23], L75R
in an Israeli-Arab family, and exon 7 deletion in Ashkenazi-
Jewish [24]) causing hypouricemia. Their allele frequency
was very rare. Common polymorphisms including MTHFR
C677T have been reported to have an association with SUA
[25,26], but the impact was limited in comparison with the
above genotypes. Accordingly, SLC22A12 258X seemed to
be one of the important genetic traits influencing SUA
among Japanese.
The present study discovered that the X allele had a sig-
nificantly larger impact in males than in females. The OR
of possessing the X allele was larger in males than in
females; 102.5 vs 25.6 for SUA < 3 mg/dL and 58.2 vs 11.9
for SUA < 4 mg/dL. The differences in mean SUA
between males and females were 0.20 mg/dL among those
with XX genotype, 0.63 mg/dL among those withWX gen-
otype, and 1.71 mg/dL among those with WW genotype.
There was no biological explanation for these phenomena.
In the present study, since the subjects with XX genotype
were few, the distriubtion of those with XX genotype might
not reflect the distribution of the population with XX geno-
type. Another limitation was that the medication influencing
SUA was not taken into account for the genotype frequency
according to the SUA level. Since the medication was com-
mon for hyperuricemia, but not for hypouricemia, the effect
due to the medication might be limited for low SUA.
Conclusions
In conclusion, this study demonstrated the SUA distribu-
tion according to SLC22A12 W258X genotype in a large
study. The effect of X allele was larger in males than in
females. Since the X allele was influential and relatively
common among Japanese, the information on the genotype
would be useful for the interpretation of individual SUA.
Since SUA distributes widely among Japanese with WX
Table 4 Odds ratio (OR) and 95% confidence interval (95% CI) of low serum uric acid (SUA) for SLC22A12 W258X
among Japanese health checkup examinees
SUA < 3 mg/dL SUA < 4 mg/dL
Genotype < 3 mg/dL 3 mg/dL ≤ OR 95% CI < 4 mg/dL 4 mg/dL ≤ OR 95% CI
Males
WW 4 3,252 1 Reference 55 3,201 1 Reference
WX or XX 17 140 102.5 33.9-309.8 79 78 58.2 38.6-87.9
Total 21 3,392 157 3,279
Females
WW 53 1,484 1 Reference 436 1,101 1 Reference
WX or XX 31 42 25.6 14.4-45.3 58 15 11.9 6.6-21.5
Total 84 1,526 494 1,116
Both sexes
Males with WW 4 3,252 1 Reference 55 3,201 1 Reference
Males with WX or XX 17 140 106.5 35.3-321.6 79 78 63.7 42.0-96.5
Females with WW 53 1,484 27.2 9.8-75.4 436 1,101 22.4 16.8-29.9
Females with WX or XX 31 42 672.6 225.4-2006.8 58 15 246.3 130.9-363.7
Interaction* 0.23 0.07-0.80 0.17 0.08-0.35
Total 105 4,918 628 4,395
*Interaction between females and X allele for low SUA.
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genotype, further studies are warranted to elucidate the
determinants of the SUA distribution among those with
WX genotype, as well as among those withWW genotype.
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